RCKT News and Press, Rocket Pharmaceuticals Inc. From 12/24/23

2023-12-24 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to i...

2023-12-06 06:45:53 ET Summary Rocket has an accepted BLA filing with a PDUFA date of 3/31/2023. The stock has experienced volatile trading patterns, with no clear explanation for these fluctuations. Rocket's lead therapeutic candidate, KRESLADI, has the potential for a signif...

2023-12-05 22:38:44 ET Summary Rocket Pharmaceuticals is a biotech company that develops gene therapies for rare and life-threatening genetic disorders. The company's pipeline includes programs for severe LAD-I and Danon disease, with potential sales of $1.3 billion by 2030. R...

2023-11-06 17:49:25 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead? Rocket Pharma gains as Cantor sees $65 price targ...

Agreement reached with FDA on Phase 2 pivotal study design of RP-L301 for PKD to support accelerated approval; Initiating single-arm, 10-patient pivotal study with primary endpoint of ≥1.5 point Hgb improvement at 12 months Initiated Phase 2 pivotal trial of RP-A501 for Danon Disea...

Rocket Pharmaceuticals Inc. (RCKT) is expected to report $-0.82 for Q3 2023

2023-10-24 14:17:52 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead? Rocket Pharmaceuticals: Thriving Gene Therapy Wit...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced presentations at the 30 th Annual Congress of the European Society of Gene &...

2023-10-19 01:20:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the health care industry. The Fund trailed the Benchmark by 217 basis points this quarte...